Stage III Esophageal Squamous Cell Carcinoma Clinical Trial
Definitive chemoradiotherapy with cisplatin with cisplatin plus 5-fluorouracil is the
standard in Western countries in esophagus cancer.But in China because of its toxic
reaction, most of patients stop the halfway.Because low toxicity, Capecitabine is widely
used in the chemotherapy of esophageal cancer.
The purpose of this experiment was to study the different cycle on capecitabine with
chemotherapy for esophageal cancer chemoradiation effect.We are prepared to within 2 years
study recruited 200 patients with esophageal cancer.The primary endpoint is overall survival
and the secondary endpoints include progression-free survival, response rate,pathologic
complete response rate and adverse events.
We recruited the patients who were pathologically confirmed with esophageal squamous cell carcinoma from the Oct 2014. The the patients was divided into two groups. Group 1: Capecitabine + chemoradiation, radiation at the end of the stop using capecitabine. Group 2: Capecitabine + chemoradiation, at the end of the radiotherapy with capecitabine consolidating treatment for 5 weeks. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02628665 -
Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
|
Phase 3 | |
Recruiting |
NCT02607540 -
Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer
|
Phase 3 | |
Recruiting |
NCT02604615 -
The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy
|
Phase 3 | |
Active, not recruiting |
NCT02025036 -
Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer
|
Phase 3 | |
Completed |
NCT02644408 -
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy
|
Phase 3 | |
Recruiting |
NCT02812641 -
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC
|
Phase 2 | |
Completed |
NCT02459457 -
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
|
Phase 3 |